These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37143061)

  • 1. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
    Riillo C; Polerà N; Di Martino MT; Juli G; Hokanson CA; Odineca T; Signorelli S; Grillone K; Ascrizzi S; Mancuso A; Staropoli N; Caparello B; Cerra M; Nisticò G; Tagliaferri P; Crea R; Caracciolo D; Tassone P
    J Transl Med; 2023 May; 21(1):301. PubMed ID: 37143061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas.
    Polerà N; Mancuso A; Riillo C; Caracciolo D; Signorelli S; Grillone K; Ascrizzi S; Hokanson CA; Conforti F; Staropoli N; Gervasi L; Di Martino MT; Arbitrio M; Nisticò G; Crea R; Tagliaferri P; Juli G; Tassone P
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AXL-Receptor Targeted 14FN3 Based Single Domain Proteins (Pronectins™) from 3 Synthetic Human Libraries as Components for Exploring Novel Bispecific Constructs against Solid Tumors.
    Hokanson CA; Zacco E; Cappuccilli G; Odineca T; Crea R
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 7. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
    Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
    Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
    [No Abstract]   [Full Text] [Related]  

  • 8. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
    Lo AA; Johnston J; Li J; Mandikian D; Hristopoulos M; Clark R; Nickles D; Liang WC; Hötzel K; Dunlap D; Pham T; Cai H; Ovacik M; Bravo-Perez D; Mai E; Slaga D; Ellerman D; Ziai J; Totpal K; Lee G; Boswell CA; Payandeh J; Wu Y; Junttila TT
    Mol Cancer Ther; 2021 Apr; 20(4):716-725. PubMed ID: 33536191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy.
    Jang S; Song J; Kim N; Bak J; Jung K; Park YW; Park BC; Kim HM
    Biomaterials; 2021 Apr; 271():120760. PubMed ID: 33774526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma.
    O'Connell RP; Liaw K; Wellhausen N; Chuckran CA; Bhojnagarwala PS; Bordoloi D; Park D; Shupin N; Kulp D; June CH; Weiner D
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38834201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
    Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
    MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
    de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
    van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
    Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
    BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
    Kamikawa T; Kimura N; Ishii S; Muraoka M; Kodama T; Taniguchi K; Yoshimoto M; Miura-Okuda M; Uchikawa R; Kato C; Shinozuka J; Akai S; Naoi S; Tomioka N; Nagaya N; Pang CL; Garvita G; Feng S; Shimada M; Kamata-Sakurai M; Aburatani H; Kitazawa T; Igawa T
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
    Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
    Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microenvironment-responsive anti-PD-L1 × CD3 bispecific T-cell engager for solid tumor immunotherapy.
    Liu D; Bao L; Zhu H; Yue Y; Tian J; Gao X; Yin J
    J Control Release; 2023 Feb; 354():606-614. PubMed ID: 36669532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.